TECNOTREE
1.8.2024 15:30:28 CEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for BSS, OSS, AI, 5G, and cloud-native technologies, has partnered with MiFibra, a leading High-Speed Broadband Internet Service Provider in Perú, to update its Operations Support Systems and transform Fulfillment and Assurance processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801164212/en/
Tecnotree and MiFibra Collaborate to Revolutionize its Operations Support Systems (Graphic: Business Wire)
The strategic partnership will allow MiFibra to fully realize the potential of its Fiber to the Home (FTTH) network infrastructure, offering several benefits, such as the capability to automate feasibility, provisioning and maintenance of services, removing complexities and delays related to manual tasks, as well offering the capability to guarantee the quality of services (QoS) and the quality of the experience (QoE). The results of this partnership will allow MiFibra to accelerate the growth of its customer base, increase customer satisfaction and strengthen its position in the market.
It will also expose TMForum's open APIs for service qualification and activation, enabling seamless integration and compatibility with a variety of protocols and network elements. MiFibra will be able to fully optimize the capacity and usage of its network infrastructure, and, through efficient resources management, it will be able to achieve operational excellence.
Carlos Villegas, CEO of MiFibra, said: "The partnership between MiFibra and Tecnotree represents a transformative step towards comprehensive provisioning with greater and better information for commercial and technical customer management. Through this strategic alliance, MiFibra will be able to evolve its commercial and technical service platforms over time by incorporating digital self-management tools for the customer, a proactive communication portal for the customer, and tools for optimizing home equipment."
Padma Ravichander, CEO of Tecnotree Corporation, said, “We are delighted with this new partnership with MiFibra to embark on a transformative journey towards digitalization and operational efficiency, by revolutionizing their infrastructure and operational support systems. By leveraging our expertise in BSS, OSS, Artificial Intelligence and 5G technologies, Tecnotree will enable MiFibra to unlock its true potential and drive growth by provisioning services quicker and assurance of quality of its services. Through increased automation and streamlined processes, we will enable fast and agile interactions at scale, which will not only fuel MiFibra's customer base, but will also fortify their market position.”
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) & Operating Support System (OSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is No. 1 on the TM Forum Open API Conformance table with 59 Open APIs, a result of our pursuit of delivering excellence, and consistently providing differentiated experiences and services to the CSPs and DSPs. Our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
About MiFibra
MiFibra is a company founded by Peruvian executives with over 20 years of experience in the telecommunications sector. It currently has broadband fiber optic networks in the departments of Piura, Lambayeque, Trujillo, and Ancash, with coverage of more than 800,000 households and over 80,000 connected customers. It has been recognized by Ookla as the leading Fixed Internet operator in terms of speed in all the departments where it operates. Its mission is to bring world-class internet service to more and more Peruvians, and its vision is to become the number one operator wherever it operates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801164212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom